Lv22
180 积分 2023-09-13 加入
T-cell engager activity of etentamig (BCMA x CD3) is potentiated by daratumumab in preclinical models of multiple myeloma
4小时前
求助中
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab
8小时前
已完结
Bortezomib enhances the efficacy of BCMA CAR-T therapy through up-regulating BCMA expression in myeloma cells
1天前
已完结
Plasma cell leukemia
28天前
已完结
Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets
4个月前
已完结
New insights into the role of antinuclear antibodies in systemic lupus erythematosus
4个月前
已完结
396P Evaluation of MUC1-C/CD3 biparatopic-bispecific (BPBS) T cell engager as an immunotherapeutic agent for the treatment of MUC1-expressing metastatic breast cancer (mBC)
5个月前
已完结
396P Evaluation of MUC1-C/CD3 biparatopic-bispecific (BPBS) T cell engager as an immunotherapeutic agent for the treatment of MUC1-expressing metastatic breast cancer (mBC)
5个月前
已关闭
Suppression of MUC1-Overexpressing Tumors by a Novel MUC1/CD3 Bispecific Antibody
5个月前
已完结
皖公网安备34019202002308
